Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Tuesday said that the resubmission of Biologics License Application (BLA) for linvoseltamab for the treatment of multiple myeloma has been ...

Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Last week, Regeneron announced a strategic research collaboration with CytomX Therapeutics within the field of conditionally activated bispecific therapeutics for the treatment of cancer.

Unfortunately, there are also some terrible issues plaguing her death, notably the issues with the late star’s ex-husband Wang Xiao Fei (汪小菲) and his mother, Zhang Lan (张兰). Recently, Chinese social ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR trial investigating EYLEA HD (aflibercept) Injection 8 mg. The QUASAR trial ...

After hours: February 13 at 6:25:24 PM EST ...